StockData

Anteris Technologies Global vs CollPlant Biotechnologies

AVR and OPHI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AVR and OPHI compare

CollPlant Biotechnologies grew revenue faster over the last twelve months (360% versus 9.0% for Anteris Technologies Global).

CollPlant Biotechnologies keeps more of each dollar of sales as profit, with a net margin of −485% compared with −4637% at Anteris Technologies Global.

CollPlant Biotechnologies scores higher on the StockData Score (9 against 5 for Anteris Technologies Global), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAVROPHI
Size and price
Market cap$518M–
Share price$5.32$3.60
Change, 1 year44.2%−81.8%
Change, 5 years–−98.0%
Beta (5Y)1.67−0.48
Employees17439
StockData Score
Total score59 (better)
Valuation score1 (better)0
Growth score13 (better)
Performance score01 (better)
Health score35 (better)
Dividend score00
Valuation
P/S222×–
P/B2.3×–
FCF yield−18.0%–
Growth
Revenue growth (TTM)9.0%360% (better)
Revenue growth, 5Y average–−17.3%
Profitability
Gross margin75.8% (better)64.8%
Operating margin−4880%−484% (better)
Net margin−4637%−485% (better)
FCF margin−4008%−398% (better)
Return on equity−93.8% (better)−149%
Return on invested capital−3856%−1245% (better)
Financial health
Debt / equity0.00 (better)0.00
Interest coverage−615.2×–
Current ratio12.45 (better)1.57
Altman Z-score5.96–
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions70.8%0.00%
Held by insiders32.6%–
Insider net buying, 12 months$44.1M–
Short interest, % of float13.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.